BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 14645238)

  • 1. E2F and Sp1/Sp3 Synergize but are not sufficient to activate the MYCN gene in neuroblastomas.
    Kramps C; Strieder V; Sapetschnig A; Suske G; Lutz W
    J Biol Chem; 2004 Feb; 279(7):5110-7. PubMed ID: 14645238
    [TBL] [Abstract][Full Text] [Related]  

  • 2. E2F proteins regulate MYCN expression in neuroblastomas.
    Strieder V; Lutz W
    J Biol Chem; 2003 Jan; 278(5):2983-9. PubMed ID: 12438307
    [TBL] [Abstract][Full Text] [Related]  

  • 3. E2F-dependent histone acetylation and recruitment of the Tip60 acetyltransferase complex to chromatin in late G1.
    Taubert S; Gorrini C; Frank SR; Parisi T; Fuchs M; Chan HM; Livingston DM; Amati B
    Mol Cell Biol; 2004 May; 24(10):4546-56. PubMed ID: 15121871
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Silencing of transcription of the human luteinizing hormone receptor gene by histone deacetylase-mSin3A complex.
    Zhang Y; Dufau ML
    J Biol Chem; 2002 Sep; 277(36):33431-8. PubMed ID: 12091390
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Both Sp1 and Sp3 are responsible for p21waf1 promoter activity induced by histone deacetylase inhibitor in NIH3T3 cells.
    Xiao H; Hasegawa T; Isobe K
    J Cell Biochem; 1999 Jun; 73(3):291-302. PubMed ID: 10321829
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Restoration of transforming growth factor-beta signaling through receptor RI induction by histone deacetylase activity inhibition in breast cancer cells.
    Ammanamanchi S; Brattain MG
    J Biol Chem; 2004 Jul; 279(31):32620-5. PubMed ID: 15155736
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DNA methyltransferase 1 knock down induces gene expression by a mechanism independent of DNA methylation and histone deacetylation.
    Milutinovic S; Brown SE; Zhuang Q; Szyf M
    J Biol Chem; 2004 Jul; 279(27):27915-27. PubMed ID: 15087453
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Retinoic acid induced downregulation of MYCN is not mediated through changes in Sp1/Sp3.
    Kanemaru KK; Tuthill MC; Takeuchi KK; Sidell N; Wada RK
    Pediatr Blood Cancer; 2008 Apr; 50(4):806-11. PubMed ID: 17554788
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trichostatin A induces transforming growth factor beta type II receptor promoter activity and acetylation of Sp1 by recruitment of PCAF/p300 to a Sp1.NF-Y complex.
    Huang W; Zhao S; Ammanamanchi S; Brattain M; Venkatasubbarao K; Freeman JW
    J Biol Chem; 2005 Mar; 280(11):10047-54. PubMed ID: 15647279
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sp1/Sp3-dependent regulation of human telomerase reverse transcriptase promoter activity by the bioactive sphingolipid ceramide.
    Wooten LG; Ogretmen B
    J Biol Chem; 2005 Aug; 280(32):28867-76. PubMed ID: 15951564
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trichostatin A, a histone deacetylase inhibitor, activates the IGFBP-3 promoter by upregulating Sp1 activity in hepatoma cells: alteration of the Sp1/Sp3/HDAC1 multiprotein complex.
    Choi HS; Lee JH; Park JG; Lee YI
    Biochem Biophys Res Commun; 2002 Aug; 296(4):1005-12. PubMed ID: 12200149
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transcription factors of the Sp1 family: interaction with E2F and regulation of the murine thymidine kinase promoter.
    Rotheneder H; Geymayer S; Haidweger E
    J Mol Biol; 1999 Nov; 293(5):1005-15. PubMed ID: 10547281
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Histone deacetylase inhibitors activate INK4d gene through Sp1 site in its promoter.
    Yokota T; Matsuzaki Y; Miyazawa K; Zindy F; Roussel MF; Sakai T
    Oncogene; 2004 Jul; 23(31):5340-9. PubMed ID: 15107822
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined IFN-gamma and retinoic acid treatment targets the N-Myc/Max/Mad1 network resulting in repression of N-Myc target genes in MYCN-amplified neuroblastoma cells.
    Cetinkaya C; Hultquist A; Su Y; Wu S; Bahram F; PĂ„hlman S; Guzhova I; Larsson LG
    Mol Cancer Ther; 2007 Oct; 6(10):2634-41. PubMed ID: 17938259
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular cloning and characterization of human nonsteroidal anti-inflammatory drug-activated gene promoter. Basal transcription is mediated by Sp1 and Sp3.
    Baek SJ; Horowitz JM; Eling TE
    J Biol Chem; 2001 Sep; 276(36):33384-92. PubMed ID: 11445565
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of the promoter of human transcription factor Sp3 and evidence of the role of factors Sp1 and Sp3 in the expression of Sp3 protein.
    Lou Z; Maher VM; McCormick JJ
    Gene; 2005 May; 351():51-9. PubMed ID: 15857802
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aberrant regulation of survivin by the RB/E2F family of proteins.
    Jiang Y; Saavedra HI; Holloway MP; Leone G; Altura RA
    J Biol Chem; 2004 Sep; 279(39):40511-20. PubMed ID: 15271987
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Balance between acetylation and methylation of histone H3 lysine 9 on the E2F-responsive dihydrofolate reductase promoter.
    Nicolas E; Roumillac C; Trouche D
    Mol Cell Biol; 2003 Mar; 23(5):1614-22. PubMed ID: 12588981
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heregulin regulates the ability of the ErbB3-binding protein Ebp1 to bind E2F promoter elements and repress E2F-mediated transcription.
    Zhang Y; Hamburger AW
    J Biol Chem; 2004 Jun; 279(25):26126-33. PubMed ID: 15073182
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential transcriptional regulation of c-myc promoter through the same DNA binding sites targeted by Sp1-like proteins.
    Majello B; De Luca P; Suske G; Lania L
    Oncogene; 1995 May; 10(9):1841-8. PubMed ID: 7753559
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.